Given that diabetic nephropathy is characterized by glomerular sclerosis and renal interstitial fibrosis and HDAC4 is also highly expressed in podocytes, it would be reasonable to speculate that treatment with tasquinimod would be effective in attenuating diabetic nephropathy and other kidney diseases due to glomerular sclerosis and interstitial fibrosis. Here, HDAC4 is linked to kidney disorder.